Co-Diagnostics Inc

For the period ended Sep 30, 2024. Filed Nov 7, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 7, 2024

CODX$0.29-9.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

Convertible Preferred Stock · Common Stock · Treasury · Additional Paid-in · Accumulated Other Comprehensive · Accumulated Earnings · Total Stockholders’
Shares · Amount · Shares · Amount · Stock · Capital · Income · (Deficit) · Equity
Balance as of December 31, 2023	-	$	-	36,108,346	$36,108	$(15,575,795)	$96,808,436	$146,700	$4,598,166	$86,013,615
Stock-based compensation	-		-	18,750	19	-	1,571,215	-	-	1,571,234
Other comprehensive income, net of tax	-		-	-	-	-	-	79,855	-	79,855
Net loss	-		-	-	-	-	-	-	(9,312,043)	(9,312,043)
Balance as of March 31, 2024	-		-	36,127,096	36,127	(15,575,795)	98,379,651	226,555	(4,713,877)	78,352,661
Stock-based compensation	-		-	632,584	633	-	1,499,025	-	-	1,499,658
Other comprehensive income, net of tax	-		-	-	-	-	-	144,653	-	144,653
Net loss	-		-	-	-	-	-	-	(7,599,318)	(7,599,318)
Balance as of June 30, 2024	-		-	36,759,680	36,760	(15,575,795)	99,878,676	371,208	(12,313,195)	72,397,654
Stock-based compensation	-		-	18,750	18	-	1,045,565	-	-	1,045,583
Other comprehensive income, net of tax	-		-	-	-	-	-	37,158	-	37,158
Net loss	-		-	-	-	-	-	-	(9,696,455)	(9,696,455)
Balance as of September 30, 2024	-	$	-	36,778,430	$36,778	$(15,575,795)	$100,924,241	$408,366	$(22,009,650)	$63,783,940

Convertible Preferred Stock · Common Stock · Treasury · Additional Paid-in · Accumulated Other Comprehensive · Accumulated Earnings · Total Stockholders’
Shares · Amount · Shares · Amount · Stock · Capital · Income · (Deficit) · Equity
Balance as of December 31, 2022	-	$	-	34,754,265	$34,754	$(14,211,866)	$88,472,935	$293,140	$39,931,031	$114,519,994
Stock-based compensation	-		-	68,750	69	-	2,168,673	-	-	2,168,742
Repurchases of common stock	-		-	-	-	(482,196)	-	-	-	(482,196)
Other comprehensive income, net of tax	-		-	-	-	-	-	178,621	-	178,621
Net loss	-		-	-	-	-	-	-	(5,755,391)	(5,755,391)
Balance as of March 31, 2023	-		-	34,823,015	34,823	(14,694,062)	90,641,608	471,761	34,175,640	110,629,770
Stock-based compensation	-		-	525,335	525	-	2,169,276	-	-	2,169,801
Repurchases of common stock	-		-	-	-	(555,734)	-	-	-	(555,734)
Other comprehensive income, net of tax	-		-	-	-	-	-	107,366	-	107,366
Net loss	-		-	-	-	-	-	-	(8,918,825)	(8,918,825)
Balance as of June 30, 2023	-		-	35,348,350	35,348	(15,249,796)	92,810,884	579,127	25,256,815	103,432,378
Stock-based compensation	-		-	18,750	19	-	2,172,146	-	-	2,172,165
Repurchases of common stock	-		-	-	-	(166,326)	-	-	-	(166,326)
Other comprehensive income, net of tax	-		-	-	-	-	-	33,522	-	33,522
Net loss	-		-	-	-	-	-	-	(5,982,194)	(5,982,194)
Balance as of September 30, 2023	-	$	-	35,367,100	$35,367	$(15,416,122)	$94,983,030	$612,649	$19,274,621	$99,489,545

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.